Thomas Miller/Linkedin
Jun 16, 2025, 15:00
Thomas Miller: Unlocking Smarter BCL-2 Inhibitor Therapies After EHA 2025
Thomas Miller, Principal Investigator at Institut Paoli-Calmettes, shared a post on LinkedIn:
“Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Excellent final day at EHA2025. Institut Paoli-Calmettes was particularly engaged by the dedicated session on BCL-2 inhibitor therapies, highlighted by Sylvain Garciaz’s insightful presentation on inherent and acquired resistance mechanisms.
This critical discussion sparks a vital question: How can we develop smarter strategies to utilize BCL-2 inhibitors, circumvent multi-drug resistance, and unlock new combination opportunities, especially for the elderly patient population?
At Institut Paoli-Calmettes, we are committed to exploring these avenues, pushing the boundaries of research to enhance treatment efficacy and improve patient outcomes.
Let’s continue this crucial conversation and collaborate on innovative solutions!”
Find more posts featuring EHA 2025.
-
Jul 2, 2026, 21:54Rob Maloney: Rare Disease Requires Relational Care
-
Jul 2, 2026, 21:53Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
-
Jul 2, 2026, 21:52Emina Curic: Improving the Understanding of Factor V Leiden in Everyday Clinical Practice
-
Jul 2, 2026, 21:49Lee Peter Bee: The Plastic in Your Blood Is Sabotaging Your Stem Cells
-
Jul 2, 2026, 21:49Atef Ahmed: The Lethal Triad and Damage Control Philosophy
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT